Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732529 | 1.00 | L3MBTL1 (0.57) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL9147485 | 0.92 | L3MBTL1 (0.46) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL27623339 | 0.85 | L3MBTL1 (0.51) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL2327090 | 0.83 | LMNA (0.61) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL28740645 | 0.83 | L3MBTL1 (0.57) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL16467682 | 0.81 | CYP2A6 (0.42) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL6530359 | 0.81 | HTR6 (0.42) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL15352702 | 0.81 | CYP2A6 (0.42) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL16467640 | 0.81 | CYP1A2 (0.42) | L3MBTL1LMNATDP1HTTSMN1; SMN2 | |
| SCHEMBL6951150 | 0.81 | LMNA (0.53) | L3MBTL1LMNATDP1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085745-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4263646-B1 | STABILIZED EPOXY-ISOCYANATE MIXTURES AND OXAZOLIDINONE CONTAINING POLYMERS OBTAINED THEREFROM | BASF SE (DE) | 2025-02-12 | — | — | EP | disclosed |
| EP-4263646-A1 | STABILIZED EPOXY-ISOCYANATE MIXTURES AND OXAZOLIDINONE CONTAINING POLYMERS OBTAINED THEREFROM | BASF SE (DE) | 2023-10-25 | — | — | EP | disclosed |
| CN-116601199-A | Stable epoxy-isocyanate mixtures and oxazolidinone-containing polymers therefrom | 巴斯夫欧洲公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022136048-A1 | STABILIZED EPOXY-ISOCYANATE MIXTURES AND OXAZOLIDINONE CONTAINING POLYMERS OBTAINED THEREFROM | BASF SE (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220107450-A1 | COLOR FILTER, SOLID-STATE IMAGING ELEMENT, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-20180312655-A1 | FOAM MATERIALS RESISTANT TO HIGH TEMPERATURES | BASF SE (DE) | 2018-11-01 | — | — | US | disclosed |
| EP-0330788-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330824-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0329903-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329905-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329902-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329904-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329932-A2 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments | MERRELL PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4788224-A | POLYISOCYANURATES, POLYOXAZOLIDINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-29 | — | — | US | disclosed |
| EP-0266730-A1 | Esters of hexadydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4179507-A | NEUROMUSCULAR PARALYSIS, MUSCLE RELAXANTS, ISOQUINOLINE DERIVATIVES | BURROUGHS WELLCOME CO. (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, CDC42BPG | L3MBTL1 3657/4885LMNA 2164/4885TDP1 3395/4885 |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | CDC42BPG, GRK3, ERBB2 | L3MBTL1 3224/4885LMNA 3861/4885TDP1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.